Table of Contents
Introduction
Diltiazem is a non-dihydropyridine calcium channel blocker (CCB) belonging to the benzothiazepine class. It is widely used in the management of hypertension, angina pectoris, and supraventricular arrhythmias. Diltiazem occupies an intermediate position between verapamil and dihydropyridines, exerting significant effects on both the heart and vascular smooth muscle. Because of its dual cardiac and vascular actions, diltiazem is a high-yield drug in pharmacology, cardiology, and clinical entrance examinations.


Mechanism of Action (Step-wise)
Diltiazem exerts its pharmacological effects by inhibiting L-type calcium channels in cardiac and smooth muscle cells.
Step-wise mechanism:
- L-Type Calcium Channels
L-type calcium channels are responsible for calcium influx during depolarization in cardiac myocytes, nodal tissue, and vascular smooth muscle. - Blockade of L-Type Calcium Channels
Diltiazem selectively inhibits L-type calcium channels on:- Cardiac myocytes
- Sinoatrial (SA) node
- Atrioventricular (AV) node
- Vascular smooth muscle cells
- Reduced Calcium Influx
Inhibition of calcium entry decreases intracellular calcium concentration. - Cardiac Effects – Negative Chronotropy
Reduced calcium influx in the SA node slows spontaneous depolarization, decreasing heart rate. - Cardiac Effects – Negative Dromotropy
In the AV node, decreased calcium conduction slows AV nodal conduction and increases refractory period. - Cardiac Effects – Negative Inotropy
Reduced calcium availability in myocardial cells decreases contractile force. - Vascular Effects – Vasodilation
In vascular smooth muscle, reduced intracellular calcium causes relaxation, leading to arterial vasodilation. - Overall Hemodynamic Outcome
- Decreased heart rate
- Reduced myocardial oxygen demand
- Lower blood pressure
- Improved coronary blood flow
Pharmacokinetics
- Absorption: Well absorbed orally
- Bioavailability: ~40% due to first-pass metabolism
- Distribution: Widely distributed; high protein binding
- Metabolism: Hepatic metabolism via CYP3A4
- Elimination: Biliary and renal excretion of metabolites
- Half-life: Approximately 3–5 hours (extended with sustained-release forms)
Dose adjustment may be required in hepatic impairment.
Clinical Uses
Diltiazem is commonly used in cardiovascular disorders:
- Hypertension
- Chronic stable angina
- Variant (Prinzmetal) angina
- Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter – rate control)
- Hypertrophic cardiomyopathy (selected cases)
It is particularly useful when both rate control and blood pressure reduction are desired.
Adverse Effects
Adverse effects are related to excessive calcium channel blockade:
- Cardiac:
- Bradycardia
- Atrioventricular block
- Worsening heart failure (rare)
- Vascular:
- Hypotension
- Peripheral edema (less than dihydropyridines)
- Gastrointestinal:
- Constipation
- Nausea
Diltiazem should be used cautiously with beta blockers due to additive cardiac depression.
Comparative Analysis (must include a table + explanation)
Comparison of Calcium Channel Blockers
| Feature | Diltiazem | Verapamil | Amlodipine |
|---|---|---|---|
| Drug class | Non-dihydropyridine | Non-dihydropyridine | Dihydropyridine |
| Primary cardiac effect | Moderate | Strong | Minimal |
| Heart rate reduction | Yes | Strong | No |
| Vasodilation | Moderate | Mild | Strong |
| Use in arrhythmias | Yes | Yes | No |
Explanation:
Diltiazem provides balanced cardiac and vascular effects, unlike verapamil (predominantly cardiac) and amlodipine (predominantly vascular). This makes diltiazem suitable for patients requiring both heart rate control and antihypertensive therapy.
MCQs (10–15)
- Diltiazem primarily blocks which channel?
a) Sodium channel
b) Potassium channel
c) L-type calcium channel
d) T-type calcium channel
Answer: c) L-type calcium channel
- Diltiazem belongs to which class of calcium channel blockers?
a) Dihydropyridine
b) Phenylalkylamine
c) Benzothiazepine
d) Piperazine
Answer: c) Benzothiazepine
- Diltiazem decreases heart rate by acting on the:
a) Ventricular myocardium
b) Purkinje fibers
c) SA node
d) Bundle branches
Answer: c) SA node
- Diltiazem slows AV conduction primarily by:
a) Sodium channel blockade
b) Potassium channel blockade
c) Calcium channel blockade
d) Beta-receptor blockade
Answer: c) Calcium channel blockade
- Diltiazem is useful in which arrhythmia?
a) Ventricular tachycardia
b) Atrial fibrillation
c) Ventricular fibrillation
d) Torsades de pointes
Answer: b) Atrial fibrillation
- Which effect is shared by diltiazem and verapamil?
a) Reflex tachycardia
b) AV nodal suppression
c) Strong peripheral edema
d) Renin activation
Answer: b) AV nodal suppression
- Diltiazem reduces myocardial oxygen demand by:
a) Increasing preload
b) Increasing contractility
c) Decreasing heart rate and contractility
d) Increasing afterload
Answer: c) Decreasing heart rate and contractility
- A contraindication to diltiazem is:
a) Stable angina
b) Hypertension
c) Second-degree AV block
d) Variant angina
Answer: c) Second-degree AV block
- Compared to amlodipine, diltiazem causes:
a) More reflex tachycardia
b) Greater heart rate reduction
c) No effect on AV node
d) Stronger vasodilation
Answer: b) Greater heart rate reduction
- Diltiazem is metabolized mainly by:
a) CYP2D6
b) CYP1A2
c) CYP3A4
d) CYP2C9
Answer: c) CYP3A4
FAQs (minimum 5)
- What is the primary mechanism of diltiazem?
Blockade of L-type calcium channels in cardiac and vascular smooth muscle. - Why does diltiazem slow heart rate?
Because calcium channels mediate depolarization in the SA and AV nodes. - Is diltiazem a dihydropyridine?
No, it is a non-dihydropyridine calcium channel blocker. - Can diltiazem be used for arrhythmias?
Yes, especially for rate control in supraventricular tachyarrhythmias. - Does diltiazem cause reflex tachycardia?
No, it typically reduces heart rate. - Why should diltiazem be used cautiously with beta blockers?
Because combined use can cause excessive bradycardia or AV block.
References
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
https://accessmedicine.mhmedical.com - Katzung BG. Basic and Clinical Pharmacology
https://accessmedicine.mhmedical.com - Tripathi KD. Essentials of Medical Pharmacology
https://www.jaypeebrothers.com - Harrison’s Principles of Internal Medicine
https://accessmedicine.mhmedical.com

I am pursuing MBA in pharmaceutical management from NIPER Hyderabad with a strong academic record and proven success in national-level pharmacy entrance exams. I secured AIR 61 in NIPER 2024 (MS/M.Pharm) and AIR 27 in NIPER MBA, along with AIR 147 in GPAT 2024 and AIR 907 in GPAT 2023. I also achieved AIR 6 in AIIMS CRE-2025 for Drug Store Keeper and was selected as a Pharmacist (AIR 61) for ESIC. Additionally, I was the Runner-Up in Round 2 of the EY Case Study Competition.
At PharmacyFreak.com, I aim to guide future pharmacists through expert content, exam strategies, and insightful resources based on real experience and academic excellence.
Mail- harsh@pharmacyfreak.com

